The Price of Life: Hazel Tau and Others vs GlaxoSmithKline and Boehringer Ingelheim

able Action addition Affidavit afford AIDS AIDS-related allow Annexure antiretroviral therapy approximately ARVs beneficiaries benefits body Boehringer Ingelheim Campaign CD4 count cell charged clinical trials combination Competition Commission complainants considered costs Council countries currently deaths disease doctor drug companies Durban economic value effect epidemic essential estimated excessive pricing Expert Extract funded further given HAART high prices Hospital human immune system important increase industry issues licenses limited living with HIV/AIDS manufacturing March means medical schemes medicines ment million month nevirapine offer opportunistic infections organisations particular patients person pharmaceutical present prevent prices charged private sector profit programme Project public health Rand reasonable receiving reduced regimen registered require result Roberts sick South Africa stop told treat treatment workers